BMS/Janssen Will Begin Phase III For Factor XIa Inhibitor Milvexian By Year-End
Phase II Showed Potential Beyond Prior Anticoagulants
BMS unveiled three Phase III indications: secondary stroke prevention, acute coronary syndrome and atrial fibrillation • Source: Shutterstock 
